J Korean Rheum Assoc.
2005 Dec;12(4):251-262.
Rituximab Treatment for the Patient with Refractory Lupus Nephritis
- Affiliations
-
- 1Department of Internal Medicine, The Hospital for Rheumatic Diseases, Hanyang University College of Medicine, Seoul, Korea. scbae@hanyang.ac.kr
Abstract
OBJECTIVE
To determine preliminary evidence for the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE).
METHODS
Four female lupus nephritis patients who had been refractory to steroid and one or more immunosuppressive therapy were treated on an open-label basis. During a 4-week period, each patient received two 500-mg infusions of rituximab and two 750-mg infusions of cyclophosphamide.
RESULTS
Patient 1, 2, and 3 were responded with rituximab treatment with improvements in SLEDAI and laboratory parameters such as C3/C4 and 24 hour urine protein. However, patient 4 had not improved with rituximab. The variation in the level of anti-double-stranded DNA antibody was different in individual patients. No significant adverse events were observed during follow-up.
CONCLUSION
This study provides an evidence for the safety and possible efficacy of B lymphocyte depletion therapy in refractory lupus nephritis. However a further randomized trial is needed to confirm the efficacy and durability of remission.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy
- Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
- A case of Lupus Nephritis
- Experience of Rituximab Treatment in Two Patients with Severe Systemic Lupus Erythematosus
- Successful treatment with rituximab in a patient with lupus cerebritis and posterior reversible encephalopathy syndrome: a case report
